LZYY(SH:603368)2022-04-27 16:00Financial Performance - The company achieved operating revenue of CNY 4.81 billion in Q1 2022, representing a year-on-year increase of 15.67%[9] - Net profit attributable to shareholders was CNY 220.95 million, up 6.35% compared to the same period last year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 218.80 million, reflecting an 11.31% increase year-on-year[9] - Total operating revenue for Q1 2022 reached CNY 4,813,503,290.88, an increase of 15.7% compared to CNY 4,161,500,720.11 in Q1 2021[27] - Net profit for Q1 2022 was CNY 230,942,512.59, representing a 2.3% increase from CNY 224,682,858.38 in Q1 2021[29] - The company reported a total profit of CNY 270,918,902.01 for Q1 2022, slightly higher than CNY 265,535,283.21 in Q1 2021[29] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.61, up from CNY 0.57 in Q1 2021[31] Revenue Breakdown - The wholesale segment generated revenue of CNY 397.20 million, a 17.12% increase year-on-year, driven by product structure optimization[9] - The retail segment reported revenue of CNY 68.68 million, up 5.87% year-on-year, supported by the integration of wholesale and retail operations[7] - The industrial segment's revenue increased by 21.10% year-on-year to CNY 13.55 million, benefiting from enhanced production capacity and market expansion[7] - Other business segments saw a substantial increase, primarily due to the growth in supply chain value-added services and third-party logistics[9] Assets and Liabilities - The total assets at the end of the reporting period reached CNY 16.96 billion, a 6.83% increase from the end of the previous year[7] - As of March 31, 2022, the total assets of Guangxi Liuzhou Pharmaceutical Co., Ltd. amounted to CNY 16,959,060,423.52, an increase from CNY 15,874,750,518.75 at the end of 2021, representing a growth of approximately 6.8%[21][23] - The company's current assets totaled CNY 14,475,465,841.86, up from CNY 13,387,644,715.92, indicating an increase of about 8.1% year-over-year[21][23] - The total liabilities increased to CNY 10,921,800,187.99 from CNY 10,068,480,649.28, which is an increase of approximately 8.5%[26] - The company's equity attributable to shareholders reached CNY 5,681,078,908.60, up from CNY 5,460,085,144.85, indicating a growth of about 4.0%[26] Cash Flow - The company reported a net cash flow from operating activities of -CNY 717.60 million, indicating a significant cash outflow during the quarter[5] - Cash flow from operating activities was CNY 3,780,131,795.51, an increase from CNY 2,798,460,579.48 in the same quarter of the previous year[32] - The net cash flow from operating activities was -717,602,736.95 CNY, an improvement from -870,629,976.99 CNY in the previous year[34] - Total cash inflow from financing activities was 1,942,151,899.92 CNY, compared to 520,908,576.10 CNY in the same period last year[36] - The net cash flow from financing activities was 225,245,769.95 CNY, a significant recovery from -838,322,732.95 CNY in the previous year[36] Expenses - Total operating costs increased to CNY 4,505,775,121.08, up 15.9% from CNY 3,883,532,851.85 in the same period last year[27] - R&D expenses rose significantly to CNY 4,107,655.99, compared to CNY 1,173,285.96 in the previous year, indicating a focus on innovation[27] - The increase in sales expenses to CNY 111,884,844.04 from CNY 107,873,839.18 reflects the company's efforts to boost market presence[27] Cash and Investments - Cash and cash equivalents decreased to CNY 3,136,317,837.42 from CNY 3,415,544,094.04, reflecting a decline of approximately 8.2%[21][23] - Cash and cash equivalents at the end of the period amounted to 2,619,072,714.35 CNY, down from 3,466,790,933.52 CNY at the beginning of the period[36] - Cash inflow from investment activities was 52,036,921.36 CNY, down from 76,074,917.46 CNY in the previous year[34] - Cash outflow for investment activities totaled 202,368,513.41 CNY, compared to 187,577,829.93 CNY in the same period last year[34] Borrowings - Short-term borrowings surged to CNY 3,500,996,717.77, compared to CNY 2,711,206,717.77, reflecting an increase of approximately 29.0%[26] - The company received 1,924,790,000.00 CNY in loans, a significant increase from 514,000,000.00 CNY in the previous year[36] - The company paid 1,352,587,034.24 CNY in debt repayments, slightly up from 1,291,000,000.00 CNY in the previous year[36] Future Outlook - The company aims to enhance its market expansion strategies and product development in the upcoming quarters[27]